Or Refractory B-cell Malignancies

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2023-04-18
Clinical Trial Update: A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies [Phase 1, Phase 2]
A clinical trial update for the tyrosine kinase inhibitor orelabrutinib (ICP-022) in relapsed/refractory B-cell malignancies across Phase 1 …